NIOX vs. MXCT, EKF, CREO, OXB, BMK, BVXP, TSTL, HVO, AMS, and APH
Should you be buying NIOX Group stock or one of its competitors? The main competitors of NIOX Group include MaxCyte (MXCT), EKF Diagnostics (EKF), Creo Medical Group (CREO), Oxford Biomedica (OXB), Benchmark (BMK), Bioventix (BVXP), Tristel (TSTL), hVIVO (HVO), Advanced Medical Solutions Group (AMS), and Alliance Pharma (APH). These companies are all part of the "medical" sector.
NIOX Group (LON:NIOX) and MaxCyte (LON:MXCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, community ranking, analyst recommendations, earnings and media sentiment.
In the previous week, MaxCyte had 2 more articles in the media than NIOX Group. MarketBeat recorded 2 mentions for MaxCyte and 0 mentions for NIOX Group. MaxCyte's average media sentiment score of 0.89 beat NIOX Group's score of 0.00 indicating that MaxCyte is being referred to more favorably in the news media.
NIOX Group has a net margin of 29.08% compared to MaxCyte's net margin of -83.00%. NIOX Group's return on equity of 11.47% beat MaxCyte's return on equity.
NIOX Group has higher earnings, but lower revenue than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.
NIOX Group has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.
NIOX Group currently has a consensus target price of GBX 77, indicating a potential upside of 4.05%. Given NIOX Group's higher possible upside, research analysts plainly believe NIOX Group is more favorable than MaxCyte.
30.0% of NIOX Group shares are held by institutional investors. Comparatively, 77.8% of MaxCyte shares are held by institutional investors. 54.5% of NIOX Group shares are held by company insiders. Comparatively, 1.2% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
MaxCyte received 152 more outperform votes than NIOX Group when rated by MarketBeat users. However, 100.00% of users gave NIOX Group an outperform vote while only 68.92% of users gave MaxCyte an outperform vote.
Summary
NIOX Group beats MaxCyte on 10 of the 17 factors compared between the two stocks.
Get NIOX Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for NIOX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NIOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NIOX Group Competitors List
Related Companies and Tools
